Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The Best Internet Mastering Stages for Expertise Improvement - 2Lily Allen 2026 'West End Girl' Tour: How to get tickets, prices, presale info and more
- 32 of Earth's rarest lightning phenomena captured simultaneously in once-in-a-lifetime photo
- 4Palestinian infant freezes to death in Gaza as Israel keeps blocking aid
- 5From Lounge chair to Money: Online Positions That Will Change Your Profession
- British-Egyptian dissident apologises for tweets as Tories push for UK deportation
- These HGTV stars made a pledge to keep their kids off smartphones. Here's how it's going.
- NASA's Perseverance Mars rover could break the record for miles driven on another planet
- People are getting their news from AI – and it’s altering their views
- Artemis II's moon-bound astronauts capture Earth's brilliant blue beauty as they leave it behind
- These 2 moon rovers used cameras and lasers to hunt for simulated water ice — and one looks like WALL-E
- Jesse Jackson hospitalized, under observation for a neurodegenerative condition
- Moon rush: These private spacecraft will attempt lunar landings in 2026
- Ergonomic Office Seats for Work spaces
